Amyl Therapeutics
June 16, 2025
Company Presentation
Brain Health
Amyl Tx develops innovative biological therapies for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s and of systemic amyloidosis.
The pathogenesis of several neurodegenerative diseases involves multiple amyloid fibrils. Each current monoclonal targets only one type of fibril. Amyl Tx ‘s unique technology allows simultaneous action on multiples amyloid fibrils thanks to a conformational binding to the structure of amyloid fibrils, together with a reduced ARIA rate and severity and an improved Blood Brain Barrier passage. We will therefore deliver ahead of competition the treatment that gathers all improvements expected by the market, following the registration of the first anti-Abeta monoclonals which present limitations in terms of scope of amyloid action, safety concern with the ARIAs and the poor BBB passage.
Company HQ City:
Liège
Company HQ State:
Liège
Company HQ Country:
Belgium
Year Founded:
2020
Lead Product in Development:
Amyl Tx demonstrated the ability to act on A beta, Tau and Alpha synuclein, and is currently optimizing the molecule in terms of potency, safety and BBB passage. End 2025 lead candidates will be validated in vivo to select a clinical candidate in 2026 and initiate clinical development early 2028 in a rare AD indication.
CEO
Dr. Pierre Vandepapelière
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
None
When you expect your next catalyst update?
Validation of clinical candidate
What is your next catalyst (value inflection) update?
By Nov
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}